Introduction: Medications for constipation can cause loose or watery stools (LoWS). As new medications become available, an understanding of patients' perceptions regarding treatment effects and satisfaction may help clinicians manage patients' expectations and inform clinical perspectives of these treatments. Linaclotide is one of several treatment options for irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC); however, little information is available on the impact of stool consistency on patient-reported bowel movement (BM) satisfaction associated with their treatment options. Methods: Data were derived from CONTOR, a longitudinal research platform combining administrative claims and patient survey data for IBS-C and CIC patients [1]. Pooled data from two patient-reported 7-day daily diaries completed at baseline and Month 12 were used to create a dataset of 2907 diaries representing 26,524 BMs for 1830 patients to understand factors influencing BM satisfaction, particularly among patients taking linaclotide. Data included bowel/abdominal symptom treatments taken in the prior 24 hours, time and 1-word description of each BM, and whether the BM was satisfactory. Binary variables were created for: medication use in the past 24 hours and categorization of the BM as LoWS (based on Bristol Stool Form Scale [BSFS] 6/7), hard or lumpy stool (HoLS, based on BSFS 1/2), or neither LoWS nor HoLS. Logistic regressions between linaclotide and LoWS analyzed the relationship between BM satisfaction and treatment. Results: Overall, BMs characterized as HoLS were satisfactory less often (19.4%) than LoWS (51.2%) and neither LoWS nor HoLS (61.2%). Patients taking linaclotide reported a similar proportion of BMs as satisfactory when described as LoWS (65.6%) or as neither LoWS nor HoLS (64.1%) [Figure]. Patients reporting linaclotide use had higher odds of reporting BMs as satisfactory (odds ratio [OR] 1.23, P<0.05) than those who had not; the odds were even greater among linaclotide users with LoWS (OR 2.05, P<0.001) when considering whether the impact of linaclotide on satisfaction depended on stool form [Table].FigureTable: Table. Model ResultsConclusion: Patients were more likely to report BMs as satisfactory for stools described as LoWS or neither LoWS nor HoLS. Compared to those not taking linaclotide, patients taking linaclotide were more likely to be satisfied, particularly those reporting LoWS.